Bayer AG Stock (DE000BAY0017): Berenberg nudges price target higher as glyphosate risk stays in focus

Bayer shares trade slightly higher on Friday after Berenberg inches up its price target and reiterates a Hold rating, while UBS sticks to a much more bullish view amid ongoing glyphosate litigation risks.

By AD HOC NEWS - Stocks & Markets Desk Team | June 12, 2026

Bayer AG shares are back in focus on Friday as fresh analyst commentary highlights how divided the market still is on the German pharma and crop-science group. According to a note reported by finanzen.net, private bank Berenberg has raised its price target slightly from 40.00 to 40.50 euros and kept a Hold rating on the stock, while UBS continues to project significantly more upside with a 52 euro target and a Buy recommendation. On Xetra, Bayer traded around 35.96 to 36.14 euros during Friday trading, putting the stock modestly in positive territory versus the prior close near 35.79 euros.

Analyst views diverge on Bayer's glyphosate overhang

The latest calls from Berenberg and UBS underline that analysts remain split on how to value Bayer's lingering glyphosate litigation risk. 4investors reports that UBS reaffirmed its Buy rating and 52 euro price target, clearly positioning itself among the optimists on the stock. In contrast, Berenberg only inched its target up from 40.00 to 40.50 euros and stuck with a Hold stance, signaling that it sees the shares as more fairly valued at current levels.

Both banks continue to focus heavily on the unresolved legal legacy tied to Monsanto's herbicide glyphosate. Berenberg puts the probability of a positive ruling for Bayer at the US Supreme Court in the so-called Durnell case at roughly 60 percent, a risk profile the analysts themselves compare to little more than a coin toss. That assessment helps explain why, despite modestly higher estimates, Berenberg is not prepared to join the bullish camp led by UBS.

UBS, on the other hand, is keeping its more aggressive valuation framework unchanged. By reiterating a 52 euro price target, UBS is effectively baking in a scenario in which Bayer gets material relief on the US litigation front and can refocus investors on its underlying operating performance. The contrast between 40.50 euros at Berenberg and 52 euros at UBS translates into a wide range of implied upside from current trading levels near the mid-30s, and that spread continues to shape sentiment around the stock.

Both analyst houses have recently fine-tuned their earnings assumptions. Berenberg has nudged its estimates higher, citing expectations for stronger margins in the pharma division and somewhat more favorable currency effects. Those changes support the modest price target increase but are not enough, in Berenberg's view, to offset the ongoing uncertainties associated with the US legal cases, which remain a central valuation swing factor.

Beyond the latest target moves, broader market commentary continues to emphasize how much equity value Bayer has lost since its Monsanto acquisition and how closely investors are watching the next court decisions. A separate analysis cited by wallstreet-online points out that Bayer has shed around 60 billion euros in market capitalization since the deal and flags two upcoming US rulings that could turn into a decisive moment for the stock, with scenarios ranging from a recovery toward 50 euros to a slide toward 30 euros. Those scenario ranges help explain why some analysts like UBS see opportunity, while others, including Berenberg, remain more cautious.

Recent management steps also feed into analysts' risk assessments. Bayer has been reshaping parts of its US business and strengthening its leadership bench, with several new senior executives appointed to focus on data, artificial intelligence and operational stabilization, according to coverage by Finanztrends. While these initiatives are more medium-term in nature, they are meant to enhance execution in both pharma and crop science, potentially improving the group's ability to navigate legal, regulatory and market challenges over time.

In Friday trading, Bayer's share price action has been relatively subdued compared with the volatility often seen after major litigation or product news. Finanzen.net cites intraday levels around 36.14 euros, up roughly 0.98 percent at one point versus the previous session. 4investors similarly notes Bayer at approximately 35.96 euros, representing a gain of about 0.47 percent. WELT also highlights that the stock recently traded near 35.98 euros, modestly above Thursday's close of about 35.79 euros. The absence of a sharp move suggests that the incremental Berenberg target hike is being absorbed as a fine-tuning rather than a game-changer.

Other intraday snapshots show that the stock's direction has not been one-way during the session. Finanzen.ch reports that at one point during Friday morning trading Bayer slipped about 0.3 percent to 35.68 euros on Xetra, putting it on the losing side of the DAX 40 at that moment. Taken together, the data points underscore that the shares are oscillating within a relatively narrow band around the mid-30s, with news-driven spikes kept in check by the persistent litigation overhang.

From a broader sell-side perspective, Bayer still enjoys a majority of positive recommendations. Wallstreet-online, citing Bloomberg data, notes that 16 of 21 tracked analysts currently rate the stock a Buy, with the average price target implying upside of more than 40 percent from current levels. That consensus signal, however, masks considerable dispersion between the most bullish and most cautious views, as the UBS and Berenberg examples illustrate.

For US-based investors looking at Bayer primarily via its Frankfurt listing and any available US-traded instruments, the debate effectively centers on how to discount the legal tail risk and how quickly Bayer can translate its pipeline and margin initiatives into sustainable earnings growth. The company remains a constituent of Germany's DAX 40 index and is followed closely across global markets, including by investors benchmarked against major European and international equity indices.

While the latest analyst updates arrived without a new earnings release, they come against the backdrop of ongoing efforts to stabilize key business segments. Bayer's management has indicated in prior communications that it is working to improve performance in its crop science division and drive efficiencies in pharma, all while managing the legal docket. As analysts adjust their models for margin assumptions and currency, the market's attention remains fixed on whether the judicial track will deliver clarity that could unlock value or, conversely, prolong the overhang.

On the trading side, order book data provided by FinanzNachrichten for Bayer's Xetra line-up show quotes clustering tightly around 35.93 to 35.97 euros at one observed snapshot, with visible bid and ask sizes in the low- to mid-thousands of shares. That pattern points to ample liquidity and a relatively orderly market, even as fundamental debates remain unresolved. For active traders, the narrow intraday spreads and continuous flow of analyst commentary can create opportunities for short-term positioning around support and resistance zones.

Given the mix of cautious and bullish analyst voices, the stock's current mid-30s price level effectively sits between the downside scenarios some commentators still fear and the upside scenarios embedded in optimistic targets like UBS's 52 euros. Against this backdrop, Berenberg's slight target lift to 40.50 euros reads less like a strong signal in either direction and more like a gradual recalibration as new information on margins, foreign exchange and litigation probabilities filters into its models.

Looking ahead, the next decisive catalysts for Bayer will likely come from the US court calendar and from the company's own updates on its pharmaceutical pipeline, crop science performance and capital allocation plans. As 4investors and wallstreet-online both emphasize, court decisions related to glyphosate cases such as the Durnell matter could meaningfully reshape market expectations for future settlement costs and, by extension, for equity value. Until that clarity emerges, the split between UBS-style optimism and Berenberg-style caution is likely to persist.

For now, the stock's modest gain on Friday and the incremental move in Berenberg's price target highlight a market that is still willing to acknowledge Bayer's operational strengths and margin potential but not yet ready to fully look past the legal risks. With most analysts still positive overall yet factoring in different litigation outcomes, Bayer remains a closely watched name on European screens and a key bellwether for how markets handle complex, long-running legal overhangs.

Key facts on the Bayer AG stock

• Name: Bayer AG
• Industry: Pharmaceuticals and crop science
• Headquarters: Leverkusen, Germany
• Core markets: Global human health, consumer health and agricultural markets
• Revenue drivers: Prescription pharmaceuticals, crop protection and seeds, consumer health products
• Listing: Xetra/Frankfurt, ticker BAYN; member of the DAX 40 index
• Trading currency: Euro (EUR)

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.